Author

Z. D. Nassar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Assay:metabolomics· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

J. Dehairs· 5 shared J. V. Swinnen· 5 shared L. M. Butler· 5 shared C. Y. Mah· 4 shared A. J. Hoy· 3 shared D. J. Lynn· 3 shared L. A. Selth· 3 shared L. G. Horvath· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

J. Dehairs

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Cis-vaccenic acid is a key product of stearoyl-CoA desaturase 1 and a critical oncogenic factor in prostate cancer

J. S. Scott, R. S. Young, L.-E. Quek, D. C. Miller, E. S. Evergren, J. Dehairs, I. R. Johnson, D. A. Brooks, M. Loda, A. J. Hoy, S. J. Blanksby, J. V. Swinnen, Z. D. Nassar, L. M. Butler

This study identifies cis-vaccenic acid as a critical oncogenic factor in prostate cancer, showing it rescues cell viability loss from SCD1 inhibition and promotes growth.

bioRxiv · Mar 28, 2024 · PreprintCell Biology

Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer

C. Y. Mah, A. D. T. Nguyen, T. Niijima, M. Helm, J. Dehairs, F. J. Ryan, N. Ryan, I. G. Mills, J. V. Swinnen, D. J. Lynn, Z. D. Nassar, L. M. Butler

This study identifies DECR2 as a key driver of treatment resistance in advanced prostate cancer by regulating lipid metabolism and cell cycle progression.

bioRxiv · Nov 5, 2022Cancer Biology

ACSM1 and ACSM3 regulate prostate cancer fatty acid metabolism to promote tumour growth and constrain ferroptosis

R. Shrestha, Z. D. Nassar, A. R. Hanson, R. Iggo, S. L. Townley, J. Dehairs, C. Y. Mah, M. Helm, M. Alizadeh-Ghodsi, M. Pickering, M. J. Watt, L.-E. Quek, A. J. Hoy, W. D. Tilley, J. V. Swinnen, , L. A. Selth

This study identifies ACSM1 and ACSM3 as AR-regulated factors that promote prostate cancer growth by enhancing fatty acid metabolism and suppressing ferroptosis.

bioRxiv · Oct 13, 2022 · PreprintCancer Biology

Lipidomic profiling of clinical prostate cancer reveals targetable alterations in lipid composition

L. M. Butler, C. Y. Mah, J. Machiels, A. D. Vincent, S. Irani, S. Mutuku, X. Spotbeen, M. Bagadi, D. Waltregny, M. Moldovan, J. Dehairs, F. Vanderhoydonc, K. Bloch, R. Das, J. Stahl, , J. V. Swinnen

The paper profiles lipidomes in prostate cancer tissues and identifies targetable lipid alterations linked to AR signaling and therapeutic response.

bioRxiv · Oct 27, 2020Cancer Biology

DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis

Z. D. Nassar, C. Y. Mah, J. Dehairs, I. J. G. Burvenich, S. Irani, M. M. Centenera, R. K. Shrestha, M. Moldovan, A. S. Don, A. M. Scott, L. G. Horvath, D. J. Lynn, L. A. Selth, A. J. Hoy, J. V. Swinnen, L. M. Butler

This study identifies DECR1 as an androgen-repressed gene that promotes prostate cancer cell survival by facilitating PUFA oxidation and preventing ferroptosis.

bioRxiv · Dec 6, 2019Cancer Biology